Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40.
Chirag D JhaveriDanni LiuMaureen G MaguireAdam R GlassmanRuben A GrigorianLee M JampolRonald M KingsleyMathew W MacCumberDaniel F MartinRaj K MaturiGisela VelezJennifer K Sunnull nullPublished in: Ophthalmology (2024)
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.